ERLEADA — Sales to customers (Note 9)
Johnson & Johnson ERLEADA — Sales to customers (Note 9) decreased by 1.0% to $949.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.1%, from $771.00M to $949.00M. Over 4 years (FY 2021 to FY 2025), ERLEADA — Sales to customers (Note 9) shows an upward trend with a 29.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration or higher demand for the drug, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of ERLEADA, a pharmaceutical product used in the tr...
Peer comparison
Comparable to specific product line revenue metrics reported by other large-cap pharmaceutical companies for their key oncology or specialty drug assets.
jnj_segment_erleada_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $302.00M | $344.00M | $384.00M | $400.00M | $450.00M | $490.00M | $541.00M | $542.00M | $567.00M | $631.00M | $647.00M | $689.00M | $736.00M | $790.00M | $784.00M | $771.00M | $908.00M | $936.00M | $959.00M | $949.00M |
| QoQ Change | — | +13.9% | +11.6% | +4.2% | +12.5% | +8.9% | +10.4% | +0.2% | +4.6% | +11.3% | +2.5% | +6.5% | +6.8% | +7.3% | -0.8% | -1.7% | +17.8% | +3.1% | +2.5% | -1.0% |
| YoY Change | — | — | — | — | +49.0% | +42.4% | +40.9% | +35.5% | +26.0% | +28.8% | +19.6% | +27.1% | +29.8% | +25.2% | +21.2% | +11.9% | +23.4% | +18.5% | +22.3% | +23.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's erleada — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported erleada — sales to customers (note 9) of $949.00M in Q1 2026.
- How has Johnson & Johnson's erleada — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's erleada — sales to customers (note 9) increased by 23.1% year-over-year, from $771.00M to $949.00M.
- What is the long-term trend for Johnson & Johnson's erleada — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's erleada — sales to customers (note 9) has grown at a 29.0% compound annual growth rate (CAGR), from $1.29B to $3.57B.
- What does erleada — sales to customers (note 9) mean?
- The total net revenue generated from sales of the oncology drug ERLEADA.